|
|
|
| 11/14/2025 15:30 |
Business Overview of Pipeline Products |
| 11/14/2025 15:30 |
Consolidated Financial Results for the Nine Months Ended September 30, 2025 (Under IFRS) |
| 08/15/2025 17:50 |
Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2025) |
| 08/13/2025 15:30 |
Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2025 (under IFRS) |
| 08/12/2025 17:30 |
Licensing Agreement for DARVIAS and episil in Southeast Asia, Oceania, Middle East, and Africa Regions, Sales Approval for episil in Singapore |
| 05/14/2025 15:30 |
Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2025) |
| 05/14/2025 15:30 |
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Under IFRS) |
| 03/24/2025 16:00 |
Solasia Announces Finance via Issuance of Warrant |
| 03/05/2025 08:00 |
Notice of the 17th Annual General Meeting of Shareholders |
| 02/20/2025 16:00 |
Announcement on Capital Reduction, Surplus Appropriation (Deficit Disposition), and Election of Directors and Auditor |
| 02/12/2025 16:10 |
Business Overview of Pipeline Products |
| 02/12/2025 16:10 |
Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 |
| 02/12/2025 16:10 |
Solasia Announces Booking of Impairment Loss and Difference Between Fiscal 2024 Consolidated Earnings Forecast and Actual Results |
| 01/06/2025 09:49 |
Solasia Announces Change in Sales Partner for episil in China |
| 01/06/2025 09:40 |
Solasia Provides Notice of Revision to Its Fiscal 2024 Earnings Forecast |
| 12/27/2024 16:00 |
Solasia Provides Notice of Revision to Full-Year Earnings Forecast and Progress on Out-Licensing DARVIAS in China |
|
